2 months ago
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $10.1 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Shares of this insulin infusion systems maker have considerably underperformed the broader market over the past year. PODD has declined 56% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.3%. In 2026, PODD stock is down 48.8%, compared to the SPX's 11.8% rise on a YTD basis.
IonQ vs. Rigetti: The Better Quantum Computing Stock for Long-Term Investors
QQQ is Still in a Negative Gamma Regime. Here's How a 'Put Wall' and Fibonacci Support Could Come Into Play.
IBM Just Hit a New Quantum Computing Milestone. How to Play IBM Stock Now.
#podd #play #systems #broader
Shares of this insulin infusion systems maker have considerably underperformed the broader market over the past year. PODD has declined 56% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.3%. In 2026, PODD stock is down 48.8%, compared to the SPX's 11.8% rise on a YTD basis.
IonQ vs. Rigetti: The Better Quantum Computing Stock for Long-Term Investors
QQQ is Still in a Negative Gamma Regime. Here's How a 'Put Wall' and Fibonacci Support Could Come Into Play.
IBM Just Hit a New Quantum Computing Milestone. How to Play IBM Stock Now.
#podd #play #systems #broader
3 months ago
What do we need to know about the Boston Celtics release of the 2026-27 NBA regular season schedule? Seen in some corners as one of the toughest slates of games to be played by any ball club in the **** ociation, the dates of which teams the Celtics are going to play, where, and when helps us put some order into our expectations for Boston's coming campaign.
What are the toughest parts? The long and easy home stands? How many back-to-back games are there going to be? When are the road trips going to go down?And which national television contests will have the measuring stick games of the season for Boston?
The hosts of the "Still Poddable" podcast, Brian Robb, Sam Packard, and Jay King, took a closer look at all of the above on a recent episode of their show. Check it out below!
Listen to "Havlicek Stole the Pod" on:
Blue Wire: https://tiny.ee/CdKp
#going #boston #celtics
What are the toughest parts? The long and easy home stands? How many back-to-back games are there going to be? When are the road trips going to go down?And which national television contests will have the measuring stick games of the season for Boston?
The hosts of the "Still Poddable" podcast, Brian Robb, Sam Packard, and Jay King, took a closer look at all of the above on a recent episode of their show. Check it out below!
Listen to "Havlicek Stole the Pod" on:
Blue Wire: https://tiny.ee/CdKp
#going #boston #celtics
3 months ago
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $11.6 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The insulin infusion systems maker is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Wednesday, Aug. 5.
Ahead of the event, ***** ysts expect PODD to report a profit of $1.38 per share on a diluted basis, up 18% from $1.17 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
#insulin #Stock
Ahead of the event, ***** ysts expect PODD to report a profit of $1.38 per share on a diluted basis, up 18% from $1.17 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
#insulin #Stock
4 months ago
Insulet Corporation (NASDAQ:PODD) is one of the most promising healthcare stocks according to Wall Street ******* ysts. On June 6, Insulet Corporation (NASDAQ:PODD) released new clinical results for two of its next-generation diabetes management systems, which management described as strong and that bring the company closer to making the systems a reality.
Cherries/Shutterstock.com
The two diabetes systems are Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes. In the first study, dubbed STRIVE pivotal trial, the company compared the current Omnipod 5 with Omnipod 6 and found that the latter improved time in tight range by 7% for type 1 adults and by 5% for type 2 patients. Overall time in range also improved across both groups. The results also show that the new system delivered up to 50% more automated insulin.
Another key finding from STRIVE was that Omnipod 6 performed far better even when patients bolused less. The company explained that this matters because one of the biggest reasons people with diabetes don't hit their targets is inconsistency in remembering or choosing to manually dose for meals. Omnipod 6 compensates for that gap.
The other study, dubbed EVOLUTION 3, achieved 64% time in range, which is a 12% improvement over baseline. The system also cut total daily insulin from 86 units down to 58 units with no accompanying weight gain, and 86% of participants reported being satisfied or highly satisfied with the system.
Cherries/Shutterstock.com
The two diabetes systems are Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes. In the first study, dubbed STRIVE pivotal trial, the company compared the current Omnipod 5 with Omnipod 6 and found that the latter improved time in tight range by 7% for type 1 adults and by 5% for type 2 patients. Overall time in range also improved across both groups. The results also show that the new system delivered up to 50% more automated insulin.
Another key finding from STRIVE was that Omnipod 6 performed far better even when patients bolused less. The company explained that this matters because one of the biggest reasons people with diabetes don't hit their targets is inconsistency in remembering or choosing to manually dose for meals. Omnipod 6 compensates for that gap.
The other study, dubbed EVOLUTION 3, achieved 64% time in range, which is a 12% improvement over baseline. The system also cut total daily insulin from 86 units down to 58 units with no accompanying weight gain, and 86% of participants reported being satisfied or highly satisfied with the system.
5 months ago
Insulet Corporation (NASDAQ: PODD) is one of the best NASDAQ stocks with high upside potential. On June 6, Insulet announced promising new clinical trial results for its next-generation tubeless Automated Insulin Delivery/AID systems, presented at the American Diabetes ******* ociation's 86th Scientific Sessions. The STRIVE pivotal trial for the upcoming Omnipod 6 showed strong glycemic outcomes and improved responsiveness to hyperglycemia, noting that the system can deliver up to 50% more automated insulin while reducing the need for manual boluses across various age groups and diabetes types.
The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system specifically for type 2 diabetes. This technology is designed to automatically adjust insulin levels without requiring manual user settings, aiming to simplify clinical workflows and remove traditional barriers to care for individuals with type 2 diabetes.
These developments align with Insulet Corporation's (NASDAQ:PODD) broader innovation strategy, which prioritizes technology that requires less daily effort from users while simultaneously improving health outcomes. By combining these advanced AID systems, the company aims to move closer to a future where managing diabetes is significantly more automated and accessible for a wider range of patients.
Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.
While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system specifically for type 2 diabetes. This technology is designed to automatically adjust insulin levels without requiring manual user settings, aiming to simplify clinical workflows and remove traditional barriers to care for individuals with type 2 diabetes.
These developments align with Insulet Corporation's (NASDAQ:PODD) broader innovation strategy, which prioritizes technology that requires less daily effort from users while simultaneously improving health outcomes. By combining these advanced AID systems, the company aims to move closer to a future where managing diabetes is significantly more automated and accessible for a wider range of patients.
Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.
While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
